Related Experiment Video
Updated: Jul 25, 2025
08:08
Quantitative Mass Spectrometric Profiling of Cancer-cell Proteomes Derived From Liquid and Solid Tumors
Published on: February 27, 2015
16.3K
The proteomic landscape of soft tissue sarcomas
Jessica Burns1, Christopher P Wilding1, Lukas Krasny1
1Division of Molecular Pathology, The Institute of Cancer Research, London, UK.
Nature Communications
|June 29, 2023
Summary
This study used proteomics to analyze soft tissue sarcomas (STS), identifying new subtypes in leiomyosarcomas and potential immunotherapy targets like the complement cascade in other STS types. Proteomic modules offer improved risk stratification and therapeutic insights for these rare cancers.
Area of Science:
- Oncology
- Proteomics
- Cancer Biology
Background:
- Soft tissue sarcomas (STS) are rare, heterogeneous mesenchymal tumors with limited therapeutic strategies.
- Comprehensive molecular characterization is crucial for improving risk stratification and treatment selection in STS.
Purpose of the Study:
- To perform comprehensive proteomic profiling of diverse soft tissue sarcoma subtypes.
- To identify novel molecular subgroups and potential therapeutic targets within STS.
- To establish proteomic signatures for improved prognostic assessment and risk stratification.
Main Methods:
- Proteomic profiling of 321 STS patient tumor specimens across 11 histological subtypes.
- Integration of proteomic data with clinical and transcriptomic information.
- Bioinformatic analysis to define proteomic subtypes and functional signatures.
Main Results:
- Identified three distinct proteomic subtypes within leiomyosarcomas with varying immune and survival features.
- Nominated the complement cascade as a potential immunotherapeutic target for undifferentiated pleomorphic sarcomas and dedifferentiated liposarcomas.
- Defined Sarcoma Proteomic Modules, with a vesicle transport protein signature independently predicting distant metastasis.
Conclusions:
- Proteomics is valuable for identifying molecular subgroups in STS, aiding risk stratification and therapy selection.
- The study provides a rich proteomic resource for future STS research and drug development.
- Novel proteomic insights into STS biology may lead to more personalized treatment approaches.
